PLCB3 and neoplasm: In PLC-β3 knock-down cells, the expression and activity of CDC42 decreased obviously, and it could inhibit the production of endothelial cells stimulated by VEGF, resulting in abnormal development and delayed growth of tumor blood vessels (82, 83).